| pubmed-article:17942233 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17942233 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17942233 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:17942233 | lifeskim:mentions | umls-concept:C1533699 | lld:lifeskim |
| pubmed-article:17942233 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17942233 | pubmed:dateCreated | 2008-2-6 | lld:pubmed |
| pubmed-article:17942233 | pubmed:abstractText | Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) linked to N-acetyl-calicheamicin 1,2-dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AML) in patients over the age of 60 years who are unfit for conventional cytotoxic therapy. In this setting, it produces a complete response (CR) rate of 13%, with another 13% achieving CR with inadequate platelet recovery (CRp). The most common adverse effects associated with GO are infusion-related reactions and myelosuppression. GO monotherapy at the dose of 9 mg/m(2) is complicated with hepatic veno-occlusive disease in approximately 5% of cases, particularly prior to or following stem cell transplantation. Attenuated doses of GO or fractionated doses appear to be equally effective and better tolerated. GO has shown remarkable activity in acute promyelocytic leukemia, particularly for the elimination of minimal residual disease. Combinations of GO with chemotherapy as induction or post-remission therapy are promising, and phase III trials are ongoing. | lld:pubmed |
| pubmed-article:17942233 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17942233 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942233 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17942233 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942233 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942233 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942233 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942233 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17942233 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:17942233 | pubmed:issn | 0305-7372 | lld:pubmed |
| pubmed-article:17942233 | pubmed:author | pubmed-author:AmadoriSergio... | lld:pubmed |
| pubmed-article:17942233 | pubmed:author | pubmed-author:StasiRobertoR | lld:pubmed |
| pubmed-article:17942233 | pubmed:author | pubmed-author:VendittiAdria... | lld:pubmed |
| pubmed-article:17942233 | pubmed:author | pubmed-author:BuccisanoFran... | lld:pubmed |
| pubmed-article:17942233 | pubmed:author | pubmed-author:EvangelistaMa... | lld:pubmed |
| pubmed-article:17942233 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17942233 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:17942233 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17942233 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17942233 | pubmed:pagination | 49-60 | lld:pubmed |
| pubmed-article:17942233 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:meshHeading | pubmed-meshheading:17942233... | lld:pubmed |
| pubmed-article:17942233 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17942233 | pubmed:articleTitle | Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. | lld:pubmed |
| pubmed-article:17942233 | pubmed:affiliation | Department of Medical Sciences, Ospedale Regina Apostolorum, Regina Apostolorum Hospital, Via S Francesco, 50, Albano Laziale, Italy. roberto.stasi@uniroma2.it | lld:pubmed |
| pubmed-article:17942233 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17942233 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17942233 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17942233 | lld:pubmed |
